000 05607nam a22005655i 4500
001 978-981-10-3349-0
003 DE-He213
005 20210118125301.0
007 cr nn 008mamaa
008 170302s2017 si | s |||| 0|eng d
020 _a9789811033490
_9978-981-10-3349-0
024 7 _a10.1007/978-981-10-3349-0
_2doi
050 4 _aR895-920
072 7 _aMMN
_2bicssc
072 7 _aMED080000
_2bisacsh
072 7 _aMKR
_2thema
082 0 4 _a616.07548
_223
245 1 0 _aPersonalized Pathway-Activated Systems Imaging in Oncology
_h[electronic resource] :
_bPrincipal and Instrumentation /
_cedited by Tomio Inoue, David Yang, Gang Huang.
250 _a1st ed. 2017.
264 1 _aSingapore :
_bSpringer Singapore :
_bImprint: Springer,
_c2017.
300 _aXII, 243 p. 112 illus., 71 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aPart 1: Chemical Biology Aspect -- Chapter 1: PET Radiotracers for Tumor Imaging (Ming Rong Zhang) -- Chapter 2. Theranostic tracers for pathway-activated systems in oncology (Lan V. Pham, Jerry L. Bryant, David Yang, and Richard J. Ford) -- Chapter 3. Optimization of Aseptic Production in PET Radiopharmaceuticals for Compliance to the Most Current GMP (Chih-Hao K. Kao) - Part 2: Engineering and Instrumentation Aspect -- Chapter 4. OpenPET enabling PET imaging during radiotherapy (Taiga Yamaya and Hideaki Tashima) -- Chapter 5. High Resolution PET/CT development (Wai-Hoi Wong, and Yuxuan Zhang) -- Part 3: Social Aspect -- Chapter 6. Ethics, Regulations and Clinical Development of Precision Medicine: Activating with molecular imaging (Chieko Kurihara, and Tomio Inoue) -- Chapter 7. Optical Imaging: How far can we go (Wenbin Ma, Sara Herrera-Rodriguez, and Hector Martinez-Valdez) -- Part 4: Clinic Aspect -- Chapter 8. Applications of UIH High Resolution PET/CT in Zhongshan Hospital (Jun Zhou, Hongcheng Shi) -- Chapter 9. Clinical evaluation of focused high-resolution breast PET (Kanae Kawai Miyake, Yuji Nakamoto) -- Chapter 10. Recent Developments with Large-bore PET/CT (Tomohiro Kaneta, Tomio Inoue) -- Chapter 11. Copper-labeled radiopharmaceuticals in oncology (Hiroaki Kurihara) -- Chapter 12. PET radiopharmaceuticals in oncology beyond FDG (Shao-Li Song, Pan-Li Li, Gang Huang) -- Chapter 13. Molecular Imaging in Oncology: Challenges and Opportunities in 21st Century (Ya-Ming Li, Ya-Ming Li, David J. Yang, and Xue-Na Li) -- Chapter 14. Visualization of Apoptosis: Annexin V imaging (Skye Hsin-Hsien Yeh, Fan-Lin Kong, Ming-Hsien Lin).
520 _aThis comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in imaging and theranostic applications. We now are at the cutting edge of providing personalized treatment with increased use in oncology of these new radiopharmaceuticals. Trends in high-resolution instrumentation development, quality assurance systems and regulatory compliance for radiopharmaceuticals, clinical evaluation of radiopharmaceuticals, and benefits and pitfalls of the current clinical FDG PET are discussed. Radiopharmaceuticals are used for diagnosis of diseases of the central nervous and cardiovascular systems and for staging, restaging, and treatment planning for cancers. Nuclear biomarkers allow precise measurement of molecular pathways on a whole-body image upon administration of functional radiolabeled agents, and nuclear imaging agents have potential use in patient selection, pharmacokinetic, dosage-finding, and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation also provide sensitive and specific answers for differential responsiveness in therapeutic outcome. This book serves as a reference for moving the discovery and development of radiopharmaceuticals from the workbench to clinical applications. It thus benefits not only clinicians but also translational research scientists—molecular biologists, chemists, imaging scientists, pharmaceutical developers, physicists, and support staff.
650 0 _aNuclear medicine.
650 0 _aOncology  .
650 1 4 _aNuclear Medicine.
_0http://scigraph.springernature.com/things/product-market-codes/H29048
650 2 4 _aOncology.
_0http://scigraph.springernature.com/things/product-market-codes/H33160
700 1 _aInoue, Tomio.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aYang, David.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aHuang, Gang.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9789811033483
776 0 8 _iPrinted edition:
_z9789811033506
776 0 8 _iPrinted edition:
_z9789811098505
856 4 0 _uhttps://doi.org/10.1007/978-981-10-3349-0
912 _aZDB-2-SME
999 _c446907
_d446907
942 _cEB
506 _aAvailable to subscribing member institutions only. Доступно лише організаціям членам підписки.
506 _fOnline access from local network of NaUOA.
506 _fOnline access with authorization at https://link.springer.com/
506 _fОнлайн-доступ з локальної мережі НаУОА.
506 _fОнлайн доступ з авторизацією на https://link.springer.com/